PBYI Puma Biotechnology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PBYI

Price (delayed)

$3.35

Market cap

$156.47M

P/E Ratio

33.5

Dividend/share

N/A

EPS

$0.1

Enterprise value

$208.71M

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights
The net income has soared by 110% YoY
PBYI's EPS has surged by 108% year-on-year
Puma Biotechnology's gross margin has decreased by 2.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pumabiotechnology.com
Peers: ARRY PFE

Key stats

What are the main financial stats of PBYI
Market
Shares outstanding
46.71M
Market cap
$156.47M
Enterprise value
$208.71M
Valuations
Price to earnings (P/E)
33.5
Price to book (P/B)
6.05
Price to sales (P/S)
0.66
EV/EBIT
11.85
EV/EBITDA
7.69
EV/Sales
0.89
Earnings
Revenue
$235.07M
EBIT
$17.61M
EBITDA
$27.15M
Free cash flow
$13.71M
Per share
EPS
$0.1
Free cash flow per share
$0.29
Book value per share
$0.55
Revenue per share
$5.04
TBVPS
$2.75
Balance sheet
Total assets
$196.26M
Total liabilities
$170.41M
Debt
$113.64M
Equity
$25.85M
Working capital
$63.57M
Liquidity
Debt to equity
4.4
Current ratio
2.32
Quick ratio
2.12
Net debt/EBITDA
1.92
Margins
EBITDA margin
11.5%
Gross margin
75.6%
Net margin
2%
Operating margin
12.3%
Efficiency
Return on assets
2.4%
Return on equity
21.5%
Return on invested capital
14.2%
Return on capital employed
11.9%
Return on sales
7.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
2.45%
1 week
2.13%
1 month
25%
1 year
72.68%
YTD
-20.8%
QTD
8.41%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$235.07M
Gross profit
$177.6M
Operating income
$28.83M
Net income
$4.81M
Gross margin
75.6%
Net margin
2%
The net income has soared by 110% YoY
Puma Biotechnology's net margin has surged by 108% YoY
The operating income has grown by 22% from the previous quarter
The operating margin has grown by 18% from the previous quarter

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
P/E
33.5
P/B
6.05
P/S
0.66
EV/EBIT
11.85
EV/EBITDA
7.69
EV/Sales
0.89
PBYI's EPS has surged by 108% year-on-year
PBYI's P/B is 73% lower than its 5-year quarterly average of 22.0 and 7% lower than its last 4 quarters average of 6.5
Puma Biotechnology's equity has increased by 20% QoQ
PBYI's P/S is 75% below its 5-year quarterly average of 2.6 but 10% above its last 4 quarters average of 0.6
The revenue has grown by 17% YoY and by 3.1% from the previous quarter

Efficiency

How efficient is Puma Biotechnology business performance
PBYI's return on sales has surged by 141% year-on-year and by 42% since the previous quarter
PBYI's ROIC has soared by 136% YoY and by 41% QoQ
The ROA has soared by 111% YoY
Puma Biotechnology's ROE has soared by 103% YoY

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The total assets is 15% more than the total liabilities
Puma Biotechnology's quick ratio has soared by 57% YoY and by 35% from the previous quarter
The company's current ratio rose by 48% YoY and by 34% QoQ
Puma Biotechnology's debt to equity has shrunk by 73% YoY and by 17% QoQ
Puma Biotechnology's equity has increased by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.